Company Overview
Snapshot
Founded in May 2016 by Yuval Taff, Magneto Thrombectomy Solutions operates with 1–10 employees. The company has raised a total of $1.85M across 5 funding rounds from 1 investor. In March 2025, the company secured a grant from the European Union’s EIC Fund.
Business overview
Magneto Thrombectomy Solutions is a Health Tech & Life Sciences company developing innovative thrombectomy solutions for removing blood clots from the vascular system. The company's core technology involves catheters that use electric fields to create an attraction with target clots, enabling removal without damaging the vessel surface and reducing distal embolization. This technology, proven effective for various clot types, is integrated into products like the eTrieve™ PE kit, custom-designed for pulmonary arteries. Magneto Thrombectomy Solutions serves the healthcare industry, specifically providers, with a focus on medical devices and medical treatment & therapeutics.
Strategic signal
In May 2022, Magneto Thrombectomy Solutions announced successful first-in-human (FIH) study results for its eTrieve™ PE kit in treating pulmonary embolism. This milestone is significant as it validates the safety and efficacy of their proprietary electric attachment technology in a clinical setting, demonstrating a reduction in RV/LV ratio and alleviation of PE symptoms. For investors, this signals strong progress in clinical development and potential for market entry in the medical device sector, particularly for thrombectomy solutions.
Log in to access full profile ›Company Intelligence Q&A
- What is Magneto Thrombectomy Solutions' primary focus?
- Magneto Thrombectomy Solutions focuses on developing innovative thrombectomy solutions for the removal of blood clots in the vascular system, utilizing electric fields to create an attraction with target clots.
- What was a key development for Magneto Thrombectomy Solutions in March 2025?
- In March 2025, Magneto Thrombectomy Solutions secured a grant from the European Union’s EIC Fund.
- What was the outcome of the first-in-human study for the eTrieve™ PE kit?
- In May 2022, Magneto Thrombectomy Solutions announced successful first-in-human results for the eTrieve™ PE kit, demonstrating a significant reduction in right ventricular to left ventricular diameter (RV/LV) ratio and alleviation of symptoms associated with pulmonary embolism.
- Which investor participated in Magneto Thrombectomy Solutions' funding round in January 2023?
- In January 2023, Peregrine Ventures participated in a funding round for Magneto Thrombectomy Solutions.
- What is the core technology behind Magneto Thrombectomy Solutions' products?
- Magneto Thrombectomy Solutions' core technology involves catheters that use electric fields to bond with the negatively charged ions of a blood clot, creating a strong grip for clot removal without damaging the vessel surface.